Abcellera Biologics Inc., of Vancouver, British Columbia, announced a multitarget and multiyear collaboration with Novartis AG, of Basel, Switzerland. Abcellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to 10 targets elected by Novartis. Under terms of the agreement, Abcellera is eligible to receive technology access, research funding, downstream milestone payments, and royalties on net sales of products. Financial terms were not disclosed.